Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
21.20M | 20.45M | 19.10M | 18.05M | 21.01M | 20.04M | Gross Profit |
17.37M | 17.04M | 14.71M | 13.98M | 13.10M | 12.20M | EBIT |
5.42M | 5.02M | 5.09M | 4.41M | 2.89M | 1.48M | EBITDA |
8.07M | 7.61M | 7.11M | 5.38M | 5.41M | 2.62M | Net Income Common Stockholders |
6.34M | 5.96M | 5.59M | 4.00M | 4.12M | 1.59M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.86M | 25.15M | 23.99M | 21.46M | 24.07M | 20.35M | Total Assets |
16.95M | 51.60M | 50.58M | 49.32M | 55.05M | 53.43M | Total Debt |
2.01M | 481.02K | 747.11K | 2.97M | 6.70M | 7.47M | Net Debt |
-1.85M | -24.67M | -23.24M | -18.49M | -17.37M | -12.87M | Total Liabilities |
5.88M | 4.74M | 4.70M | 6.42M | 9.91M | 10.85M | Stockholders Equity |
11.07M | 46.85M | 45.88M | 42.90M | 45.14M | 42.58M |
Cash Flow | Free Cash Flow | ||||
9.78M | 6.89M | 7.96M | 6.05M | 5.08M | 3.55M | Operating Cash Flow |
9.84M | 6.96M | 8.86M | 6.10M | 5.40M | 4.20M | Investing Cash Flow |
-65.41K | -100.71K | -903.19K | 1.32M | -318.87K | -650.42K | Financing Cash Flow |
-4.99M | -5.70M | -5.43M | -10.03M | -1.36M | -1.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $409.57M | 67.50 | 14.17% | 0.31% | 9.73% | 22.33% | |
76 Outperform | $445.16M | 34.55 | 6.11% | ― | 7.76% | ― | |
70 Outperform | $554.25M | 134.67 | 1.94% | ― | 3.62% | -53.21% | |
60 Neutral | $11.59B | 10.44 | -7.23% | 2.94% | 7.46% | -10.66% | |
54 Neutral | $410.90M | ― | -64.59% | ― | 5.33% | 58.41% | |
54 Neutral | $595.99M | ― | -46.57% | ― | -2.39% | -2961.26% | |
51 Neutral | $360.63M | ― | 48.46% | ― | -0.61% | -1.61% |
ReposiTrak announced its financial results for the second fiscal quarter ended December 31, 2024, reporting a 7% increase in total revenue to $5.5 million and a 12% rise in net income to common shareholders. The company highlighted growth across all business lines, driven by increasing demand for food safety and compliance solutions ahead of the FSMA 204 deadline in 2026. The company is well-positioned to capitalize on industry endorsements and partnerships, with a significant increase in deferred revenue signaling continued growth. ReposiTrak ended the quarter with a strong cash position and no bank debt, continuing to invest in traceability solutions and returning capital to shareholders through dividends and share buybacks.